TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Morbidity Secondary to Stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Post-operative Recovery Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prenatal Care Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient Expectations Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of general surgical emergencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Bleed Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hospital Anxiety and Depression Scale - Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hospital Anxiety and Depression Scale - Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Impact of Events Scale-Revised - Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adhesiolysis Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number and location of enhancing brain lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Depth of lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum fluorescence loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erradication of Demodex mites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Diffusion capacity of the lungs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Subjects Maintaining Protective Anti-HAV Antibody Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tacrolimus Area under the curve (AUC 0-24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type, severity, and incidence of ocular and systemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Dementia Rating scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Standardized Alzheimer's disease Assessment Scale -cognitive subscale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rates of local and systemic reactogenicity events
Endpoint domain: Adverse events/effects
Primary endpoint: Development of adverse events at any time point during the study
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric mean titer (GMT) of H7N9-specific serum hemagglutination inhibition (HAI) and/or microneutralization (MN) antibody responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rates of H7N9-specific serum HAI and/or MN antibody responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Severity of Acute Pancreatitis (AP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical muscle function tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of patients who develop large varices (Gd 3 or Gd 4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Assessment of SpondyloArthritis International Society Criteria (ASAS20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-week infant mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Pain area index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Urinary biomarkers of NNK metabolic activation and detoxification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma levels of hydroxyoctadecadienoic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decline in Serum Prostate Specific Antigen (PSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: newly developed or exacerbated organ dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Emotional Self-Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Internalizing Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Externalizing Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of in-hospital cardiac arrests
Endpoint domain: Mortality/survival
Primary endpoint: Change in overnight fasting plasma Phe
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in overnight fasting plasma Tyr
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in overnight fasting blood Phe
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in overnight fasting blood Tyr
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Granulocyte transplantation living standards
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet transplantation living standards
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect of cell transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulse wave change from baseline during EVAR (force sensor)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulse wave change from baseline during EVAR (PPG sensor)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Swallowing behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Repeat Open Application Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with no typical absence seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Response of cervical cancer to radiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: All cause health care costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean Change From Baseline in Daytime Symptom Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ratio of proteinuria / creatininuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Requests to Initiate Someone Into Drug Injection
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Efficacy of stimulation of GPI versus GPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Urethral Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum Urethral Closure Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Glycemia Area under the plasma glucose concentration curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cognitive decline assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of Patient Samples That Maintained Platelet Inhibition Levels of Greater Than or Equal to 60%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Patients That Maintained Platelet Reaction Units (PRU) < 240
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Vertigo severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects achieving blood pressure goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of subjects achieving LDL-C goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: anti-SGC IgG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: rate of all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Enuresis frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multi-luminance Mobility Testing (MLMT), Bilateral
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Next Seizure or Rescue Medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants With an Event (Next Seizure or Rescue Medication)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in cognitive performance on a Choice Reaction Time task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in cognitive performance on a Rapid Visual Information Processing task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in cognitive performance on a combined Choice Reaction Time and Rapid Visual Information Processing task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in cognitive performance on a Letter Memory Task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: AUCinf(dn)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax(dn)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum vitamin D 25 Hydroxy Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Marrow Density Results (DMD, DEXA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic cardioembolic event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Procedure or device-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Positive and Negative affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Distress level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Pain level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4 Month Progression-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: T1% measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of cases contributing to final diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Systolic blood pressure during stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gilliam Autism Rating Scale (GADS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: verbal fluency task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Theory of mind
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Ki-67 proliferation marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of development of a parastomal hernia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Subjective Cognitive Self-Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Objective Cognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of achievement in SDAI remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Human Serum Bactericidal Activity (hSBA) Adjusted Geometric Mean Titers (GMTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects With hSBA Titers Greater Than or Equal to the Lower Limit of Quantitation (LLOQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects With a 4-fold Increase in hSBA Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Physical Impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infectious score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: BIS (Bispectral Index) variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom From MRI Scan-related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Right Atrial (RA) Capture Threshold @0.5 Millisecond (ms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Right Ventricular (RV) Capture Threshold @0.5ms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incisomaxillary angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of abuse
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Plasma Concentration Time Curve of IW-1973 (AUC[0-inf])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of IW-1973
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cross sectional area of type II muscle fibers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: COPD Symptom Burden (CAT Questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: COPD Symptom Burden (mMRC Dyspnea Scale)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: fear response
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent of patients that have cleared HPV16 at Month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in 24h-systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Forced expiratory volume in one second (FEV1 AUC0-12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Histological changes in proliferation and apoptosis markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best response according to RECIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Arterial Blood Gases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response rate (CR) at 48 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity of DBT for breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Thrombin generation measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Efficacy of FITpatch compared to standard opioid treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of FITpatch compared to standard opioid treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Symptom control change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: changes of ALSFRS-R score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Self-Test Fingerstick Blood Glucose Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Composite of Death From Vascular Causes, Myocardial Infarction, and Stroke
Endpoint domain: Mortality/survival
Primary endpoint: Major Bleeding Event
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change in Severity of Alopecia Tool Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically Significant Change From Baseline in Physical Examination Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically Significant Change From Baseline in Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Laboratory Abnormalities Reported as TEAE
Endpoint domain: Adverse events/effects
Primary endpoint: Final diagnosis using MS - Spatial dissemination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final diagnosis using MS - Time dissemination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of NMO-SD with positive anti-AQP4 Antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of NMO-SD with anti-AQP4 negative antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target Vessel MI (TV MI)
Endpoint domain: Mortality/survival
Primary endpoint: Functional Health
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: tissular and plasma kinetics of ertapenem
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Serum Concentration (Cmax) of Belatacept
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of Maximum Observed Serum Concentration (Tmax) of Belatacept
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Half-life (T-HALF) of Belatacept
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects With a Complete Response to Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a Spontaneous Bowel Movement (SBM) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: degree of correction of facial aging signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emax_urge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emax_plst
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posttraumatic growth (PTG)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Posttraumatic stress (PTSS/PTSD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Response in Serum Alanine Aminotransferase (ALT) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Increased level of myocardial fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Knee function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Transfusions Needed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Displacement of orbital structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volumetric orbital difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface comparison of bony orbits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Red Cell Survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With a Pathogen Identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Patient Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Long term safety of A-623
Endpoint domain: Adverse events/effects
Primary endpoint: American Academy of Othopaedic Surgeons lower limb and hip scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of time in tight glycemic control (80-140 mg/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hematological toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Changing movement in gaze
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: body composition measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Accuracy of Estimated Changes in Stroke Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Activated Clotting Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants Based on Tumor Response Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sustained Virologic Response
Endpoint domain: Physiological/clinical
Primary endpoint: Change in alveolar ridge width (buccal-lingual)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in alveolar ridge height (apical coronal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to relapse of iron deficiency anaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Radiographic assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes